Moneyextra Sharedealing

On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.


On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 2.4 billion in the period from 10 August 2009 to 18
December 2009.

Since the announcement as of 2 November 2009, the following
transactions have been made under the programme:


                        Number of shares    Average      Transaction
                                         purchase price  value, DKK
Accumulated, last
announcement                   4,669,099                1,490,518,113
2 November 2009                   75,000       315.9100    23,693,250
3 November 2009                   75,000       316.9650    23,772,375
4 November 2009                   75,000       323.8510    24,288,825
5 November 2009                   80,000       324.2290    25,938,320
6 November 2009                  115,000       320.5820    36,866,930
Accumulated under the
programme                      5,089,099                1,625,077,813


Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 57,850 B shares in the
period from 2 November 2009 to 6 November 2009. The shares in these
transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of
29,838,977 treasury shares, corresponding to 4.8% of the share
capital. The total amount of shares in the company is 620,000,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:

Media:                 Investors:

Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919

                       Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937

Company Announcement no 67 / 2009

This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.